reports
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...
MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...
Very sharp increase in EBITDA, cash generation and debt reduction in H...
Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 PRESS RELEASE Loudéac, 2 October 2025 Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 Outlook for 2025: continued growth, improvement in operating profitability and debt reduction WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its consolidated results for the first half of 2025. At its meeting on 1 October 2025, the Board of Directors approv...
Très forte hausse de l’EBITDA, génération de cash et baisse de l’endet...
Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 COMMUNIQUE DE PRESSE Loudéac, 2 octobre 2025 Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 Perspectives 2025 : poursuite de la croissance, amélioration de la rentabilité opérationnelle et désendettement WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, publie aujourd’hui ses résultats consolidés du 1er semestre 2025. Le Conseil d’administration du 1er octobre 2025 a...
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
- Jacob Mekhael
- Mathijs Geerts Danau
MaaT Pharma 1H25 results confirm timelines, runway to end Feb 2026
MaaT reported 1H25 results with € 2.4m in revenues from the early access program (1H24: € 1.7m) for MaaT013 in aGvHD, which points to increased demand for the product ahead of a potential EU approval in 2H26. Pipeline timelines were reiterated and we look forward to the final data from the phase 3 trial for MaaT013 in aGvHD for confirmation of the initial survival data reported in January 2025 (54% at 1-year). Beyond aGvHD, data from the phase 2 trial of MaaT013 in combination with ICI in metast...
- Guy Sips
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
Revenue growth of 6.4% in H1 2025
Revenue growth of 6.4% in H1 2025 PRESS RELEASE Loudéac, 3 September 2025 Revenue growth of 6.4% in H1 2025 Growth in all of the Group’s activities Improvement in EBITDA expected over full-year 2025 WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in consulting, services and distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its revenue figures for Q2 2025 and H1 2025. In millions of euros, unaudited Q2 2024Q2 2025Change H1 2024H1 2025ChangeFarming Supplies 32.833.7+2.7% 62.765.1+3.9%Farming Production 2.93...
Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025
Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025 COMMUNIQUE DE PRESSE Loudéac, le 3 septembre 2025 Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025 Toutes les activités du Groupe sont en progression Amélioration de l’EBITDA anticipée sur l’exercice 2025 WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chiffre d’affaires du 2ème trimestre 2025 et en cumul sur ...
- Jacob Mekhael
MaaT Pharma Secures € 37.5m tranched EIB financing
MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Bilan semestriel du contrat de liquidité
Bilan semestriel du contrat de liquidité COMMUNIQUE DE PRESSE Loudéac, 7 juillet 2025 Bilan semestriel du contrat de liquidité Au titre du contrat de liquidité confié par la société WINFARM au CREDIT INDUSTRIEL ET COMMERCIAL, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 1 528 titres16 614,04 € Au cours du 1er semestre 2025, il a été négocié un total de : Achat32 696 titres125 633,06 EUR667 transactionsVente35 509 titres133 331,01 EUR605 transactions Il est rappelé que lors de la signature du contrat, les moyens suivants figuraient au compte...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
MaaT Pharma Business update highlights upcoming priorities, final ARES...
MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
- Jacob Mekhael
MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD
MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.